---
title: "Argan, Inc. Stock 12‑Month Price Target Cut to $679.8, Implies 8% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292385755.md"
description: "Argan, Inc.'s average 12-month price target was lowered to $679.8 by five analysts, down from $683.83, implying an 8% upside based on the July 10 closing price. Forecasts range from $500 to $860 per share. The consensus rating remains 'Buy', comprising two Buy ratings and three Hold ratings."
datetime: "2026-07-11T22:20:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292385755.md)
  - [en](https://longbridge.com/en/news/292385755.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292385755.md)
---

# Argan, Inc. Stock 12‑Month Price Target Cut to $679.8, Implies 8% Upside

-   According to estimates from 5 analysts, Argan, Inc. stock's average price target has fallen from $683.83 to $679.8, with forecasts ranging from $500 to $860 per share
-   Based on the Jul. 10 closing price, the updated target implies approximately 8% potential upside
-   Consensus rating remains at “Buy” across 5 covering analysts, with 2 Buys, 3 Holds and 0 Sells

Explore more price target data and ratings for Argan, Inc. on the , and track all previous and future analyst recommendations for Argan, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AGX.US](https://longbridge.com/en/quote/AGX.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Argan director John R. Jeffrey Jr disposes of common shares worth $3.31 million](https://longbridge.com/en/news/294867826.md)
- [Argan unit SMC completes acquisition of ValCor for about $8.3 million](https://longbridge.com/en/news/294871056.md)
- [Should White Mountains (WTM) Investors React to Strong Q2 Earnings and a Major Share Buyback?](https://longbridge.com/en/news/296004368.md)
- [Should FDA Clearance Of QIAstat-Dx Sepsis Panel Require Action From Qiagen (QGEN) Investors?](https://longbridge.com/en/news/296027748.md)
- [Avalo Therapeutics CMO Mittie Doyle disposes of 679 common shares worth $13,580](https://longbridge.com/en/news/295703574.md)